Nevertheless, a number of metabolic parameters were improved, and the lowering of plasma insulin by glucocorticoid blockade may, of itself, be advantageous since in NAFLD, despite resistance to the effect of insulin to suppress gluconeogenesis, sensitivity to promotion of de novo lipogenesis is retained (24); glucocorticoid blockade may therefore also reduce hepatic lipogenesis, although this was not tested in our acute intervention study. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.